1. Home
  2. GRMN vs ALNY Comparison

GRMN vs ALNY Comparison

Compare GRMN & ALNY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Garmin Ltd. (Switzerland)

GRMN

Garmin Ltd. (Switzerland)

HOLD

Current Price

$267.19

Market Cap

49.4B

Sector

Industrials

ML Signal

HOLD

Logo Alnylam Pharmaceuticals Inc.

ALNY

Alnylam Pharmaceuticals Inc.

HOLD

Current Price

$309.84

Market Cap

42.7B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
GRMN
ALNY
Founded
1990
2002
Country
Switzerland
United States
Employees
N/A
115
Industry
Industrial Machinery/Components
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
49.4B
42.7B
IPO Year
2000
2004

Fundamental Metrics

Financial Performance
Metric
GRMN
ALNY
Price
$267.19
$309.84
Analyst Decision
Buy
Strong Buy
Analyst Count
6
28
Target Price
$256.40
$471.00
AVG Volume (30 Days)
585.5K
1.0M
Earning Date
04-29-2026
04-30-2026
Dividend Yield
1.57%
N/A
EPS Growth
17.67
206.88
EPS
8.59
2.33
Revenue
$7,245,519,000.00
$1,037,418,000.00
Revenue This Year
$12.15
$52.67
Revenue Next Year
$8.69
$31.48
P/E Ratio
$31.11
$132.27
Revenue Growth
15.06
22.88
52 Week Low
$178.74
$231.76
52 Week High
$273.32
$495.55

Technical Indicators

Market Signals
Indicator
GRMN
ALNY
Relative Strength Index (RSI) 71.06 42.62
Support Level $228.60 $306.07
Resistance Level N/A $332.08
Average True Range (ATR) 5.46 11.58
MACD 2.14 -1.06
Stochastic Oscillator 86.69 12.67

Price Performance

Historical Comparison
GRMN
ALNY

About GRMN Garmin Ltd. (Switzerland)

Garmin produces GPS-enabled hardware and software for five sectors: fitness, outdoors, automotive, aviation, and marine. Garmin has built a strong reputation for durable, high-precision devices through a vertically integrated design and manufacturing approach. The company's product lines include smartwatches, fitness trackers, communication equipment, and a comprehensive suite of systems for marine and aviation navigation. Garmin operates globally, with its business focused primarily on North America and Europe.

About ALNY Alnylam Pharmaceuticals Inc.

Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam's commercial RNAi therapeutic products include Onpattro and Amvuttra (for hATTR amyloidosis), Givlaari (for acute hepatic porphyria), and Oxlumo (for primary hyperoxaluria type 1), all developed and commercialized by Alnylam. Plus, Leqvio (for hypercholesterolemia) and Qfitlia (for hemophilia A or B), which are being commercialized by Alnylam's partners, Novartis and Sanofi, respectively. It also has several clinical programs across various therapeutic areas, including cardio-metabolic diseases, neuroscience, and hematology.

Share on Social Networks: